Stocks

Drugmaker stocks slammed over Zantac lawsuit concerns

Thousands of Zantac users have filed cases against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health risks.

SEC investigating Melvin Capital Management

The SEC is investigating Melvin Capital Management's risk controls and investor disclosure after the hedge fund was crippled by the meme-stock rally last year.

Bed Bath & Beyond downgrade slams stock

Investment firm Baird has placed an underperform rating and $4 price target on Bed Bath & Beyond's stock. The retailer's shares are down more than 36%.